15704 Federal Register / Vol. 72, No. 62 / Monday, April 2, 2007 / Notices 

Type of respondent 

Estimated 

number of 

respondents 

Frequency of 

response 

Estimated 

number of 

responses 

Average hours 

per response 

Annual hour 

burden 

Respondent 

cost** 

Pilot RDD screener only .......................... 133 1 133 .0833 11 $176 

Pilot RDD screener and interview ........... 200 2 400 *.2500 100 1,600 

Additional RDD screeners for advance 

materials test ........................................ 450 1 450 .0833 37 592 

Pilot mail survey ....................................... 640 1 640 .3333 213 3,408 

RDD screener only .................................. 2,333 1 2,333 .0833 194 3,104 

RDD screener and interview .................... 3,500 2 7,000 *.2500 1,750 28,000 

Mail survey ............................................... 3,500 1 3,500 .3333 1,167 18,672 

Telephone screener only for mail followup .................................................... 457 1 457 .0833 38 608 

Telephone screener and interview for 

mail followup ......................................... 457 2 914 *.2500 229 3,664 

Total .................................................. 11,670 ........................ 15,827 ........................ 3,739 59,824 

* (0.833 + 0.4167) / 2 = 0.2500. 

** Hourly wage rate = $16.00. 

Request For Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Direct Comments To OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding estimated public 

burden and associated response time, 

should be directed to the: Office of 

Management and Budget, Office of 

Regulatory Affairs, New Executive 

Office Building, Room 10235, 

Washington, DC 20503, Attention: Desk 

Office for NIH. To request more 

information on the proposed project or 

to obtain a copy of the data collection 

plans and instruments, contact Bradford 

W. Hesse, PhD, Project Officer, National 

Cancer Institute, NIH, EPN 4068, 6130 

Executive Boulevard MSC 7365, 

Bethesda, Maryland 20892–7365, or call 

non-toll-free number 301–594–9904, or 

FAX your request to 301–480–2198, or 

E-mail your request, including your 

address, to hesseb@mail.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

Dated: March 23, 2007. 

Rachelle Ragland-Greene, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. E7–6064 Filed 3–30–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

High-Level Expression and Purification 

of Untagged and Histidine-Tagged 

Human Immunodeficiency Virus type-1 

(HIV–1) Reverse Transcriptase 

Description of Technology: This 

invention includes plasmids and 

protocols to express and purify large 

quantities of histidine-tagged and 

untagged HIV–1 reverse transcriptase 

(RT). Conditions have been optimized 

for overexpression and purification of 

p66 and p51 heterodimer RT in E. coli. 

High-level of expression was reached as 

RT represented approximately 30%–

40% of total cell proteins. The subject 

invention enables the purification of 

large quantities of heterodimer RT 

necessary for structural and kinetic 

studies and facilitates subunit-specific 

amino acid alterations essential for 

structure/function investigations. 

Applications: Research Tool. 

Development Status: In vitro data 

available. 

Inventors: Samuel H. Wilson, 

Rajendra Prasad, Esther W. Hou 

(NIEHS). 

Related Publication: EW Hou, R 

Prasad, WA Beard, SH Wilson. Highlevel expression and purification of 

untagged and histidine-tagged HIV–1 

reverse transcriptase. Protein Expr Purif. 

2004 Mar;34(1):75–86. 

Patent Status: HHS Reference No. E–

141–2007/0—Research Tool. 

Licensing Status: Available for nonexclusive licensing as biological 

material and research tool. 

Licensing Contact: Sally Hu, PhD; 

301/435–5606; HuS@mail.nih.gov. 

Methods of Determining the Prognosis 

of an Adenocarcinoma 

Description of Technology: Available 

for licensing and commercial 

development is a novel method for 

determining the prognosis of a subject 

with adenocarcinoma in an organ, such 


hsrobinson on PROD1PC76 with NOTICES
Federal Register / Vol. 72, No. 62 / Monday, April 2, 2007 / Notices 15705 

as the lung, and to aid in the selection 

of a specific therapeutic regimen. Lung 

adenocarcinoma (AC) is the 

predominant histological subtype of 

lung cancer, which is the leading cause 

of cancer deaths worldwide. The risk of 

metastasis remains substantial in AC 

patients, even when a curative resection 

of early-stage AC is performed. The 

prognosis includes the determination of 

the likelihood of survival, the likelihood 

of metastasis, or both. The method 

includes quantization of the expression 

of a plurality of Th1 and Th2 cytokines 

of interest in the adenocarcinoma and in 

non-cancerous tissue in the organ. 

Altered expression of one or more of the 

Th1 and Th2 cytokines in the 

adenocarcinoma as compared to the 

non-cancerous tissue determines the 

prognosis for the subject. The method is 

capable of distinguishing patients with 

lymph node metastasis versus those 

with short term survival. Furthermore, 

methods are provided for evaluating the 

effectiveness of anti-cancer agents. 

Applications: Prognosis of 

adenocarcinoma, aid in the selection of 

specific therapeutic regimens and 

evaluation of the effectiveness of anticancer agents. 

Development Status: The technology 

is in early stage of development. 

Inventors: Curtis C. Harris, Masahiro 

Seike, Xin Wei Wang (NCI). 

Patent Status: 

1. U.S. Provisional Application No. 

60/830,936 filed 14 Jul 2006 (HHS 

Reference No. E–263–2006/0–US–01). 

2. U.S. Provisional Application No. 

60/885,101 filed 17 Jan 2007 (HHS 

Reference No. E–085–2007/0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Cristina 

Thalhammer-Reyero, PhD, M.B.A.; 301/ 

435–4507; thalhamc@mail.nih.gov. 

Codon Optimized Genes for Subunit 

Vaccines 

Description of Technology: Available 

for licensing from the NIH are gene 

constructs that express immunogenic 

proteins based on viral genes that have 

been optimized for expression in 

mammalian cells. Using vaccine vectors 

expressing respiratory syncytial virus 

(RSV) proteins from the optimized 

genes, this technology was shown to 

result in a potent RSV-specific cellular 

immune responses with favorable 

phenotypic patterns. Such optimized 

genes could be essential for 

development of an effective RSV 

subunit vaccine. Further, this 

optimization could have possible 

application to gene-based vectors for 

other viral vaccines. 

Potential Applications of Technology: 

Vaccines; Improved protein expression. 

Inventors: Barney S. Graham and 

Teresa R. Johnson (VRC/NIAID). 

Patent Status: U.S. Provisional 

Application No. 60/872,071 filed 30 

Nov 2006 (HHS Reference No. E–326–

2006/0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Susan Ano, PhD; 

301/435–5515; anos@mail.nih.gov. 

Dual Expression Vector for DNA 

Vaccines 

Description of Technology: Available 

for licensing from the NIH is an 

expression vector for improved DNA 

vaccines. Activation of co-stimulatory 

molecules (e.g. signaling molecules, 

cytokines, chemokines) and the timing 

of the activation are important for 

adaptive immune response. This 

technology describes a new vector that 

expresses an antigen and a costimulatory molecule, the latter after a 

delay to allow accumulation of the 

antigen. It is known that in some 

circumstances an optimal immune 

response is achieved by administration 

of a co-stimulatory molecule after 

antigen delivery. The subject technology 

improves upon the existing concept by 

providing a vector for accomplishing 

this optimization in a single step. 

Exemplary animal studies have shown 

that the delayed expression of some costimulatory molecules in important 

signaling pathways resulted in 

enhancement of the cellular and/or 

humoral immune responses using HIV 

Env as a representative antigen. 

Potential Applications: Improved 

DNA vaccines. 

Inventors: Gary J. Nabel and Wataru 

Akahata (VRC/NIAID). 

Patent Status: 1. U.S. Provisional 

Application No. 60/737,896 filed 18 

Nov 2005 (HHS Reference No. E–043–

2006/0–US–01). 

2. PCT Application No. PCT/US2006/ 

044552 filed 20 Nov 2006 (HHS 

Reference No. E–043–2006/2–PCT–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Susan Ano, PhD; 

301/435–5515; anos@mail.nih.gov. 

Methods and Systems for Efficient 

Analysis and Microdissection of Intact 

Biological Specimens 

Description of Technology: Efficient 

and accurate analysis of intact biological 

specimens is needed to provide 

information related to a broad range of 

pathologies as well as normal 

physiological states. The available 

technology includes novel systems, 

methods, and platforms for selective 

analysis of biological material such as 

whole cells, tissues and tumors. This 

platform may be used to identify and 

independently characterize specific 

components, such as cells, proteins, 

nucleic acids or other molecules that 

make-up the specimen. 

The methods include placing the 

sample of interest on a surface such as 

a membrane, and activating the surface 

at selected sites adjacent to the section 

of interest. The activated sites become 

permeable and the cells or cell 

components adjacent to the permeable 

sites can then be selectively extracted 

and their content analyzed by standard 

biochemical procedures. In addition, the 

extract may be applied to microarray 

devices, such as cDNA arrays, for 

analysis of gene expression etc. The 

technique presents a convenient 

alternative to existing methods of tissue 

microdissection. For further 

convenience, the technique can be 

directly combined with a variety of 

analytical devices such as ELISAs, 

microarray biochips, or other devices 

which include multiple regions carrying 

multiple capture molecules. 

Applications: Analysis of biological 

specimens such as whole cell tissues 

and tumors; High throughput analysis of 

individual components of intact 

biological specimens. 

Inventors: Michael R. Emmert-Buck 

(NCI), Chad R. Englert-Haldeman (NCI), 

Robert F. Bonner (NICHD), and Lance A. 

Liotta (NCI). 

Patent Status: 1. Patent Cooperation 

Treaty Application No. PCT/US01/ 

08095 filed 14 Mar 2001, which 

published as WO 02/10751 on 07 Feb 

2002; claiming priority to 26 Jul 2000 

(HHS Reference No. E–197–2000/0–

PCT–02). 

2. National Phase Applications in: 

a. U.S., Serial No. 10/333,374 filed 10 

Jul 2003 (HHS Reference No. E–197–

2000/0–US–03). 

b. Canada, Serial No. 2415864 filed 14 

Mar 2001 (HHS Reference No. E–197–

2000/0–CA–04). 

c. Europe, Serial No. 01918647.0 filed 

14 Mar 2001 (HHS Reference No. E–

197–2000/0–EP–05). 

Licensing Status: Availability for nonexclusive or exclusive licensing. 

Licensing Contact: Susan Ano, PhD; 

301/435–5515; anos@mail.nih.gov. 

Dated: March 26, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–6066 Filed 3–30–07; 8:45 am] 

BILLING CODE 4140–01–P 


hsrobinson on PROD1PC76 with NOTICES